Peptide Decoding
New?New to peptides?Start here →
Decoding

HM15275_Dosage, benefits & legal status

Also known as HM15275, LA-GLP/GIP/GCG, HM-OBCT-201

Published November 17, 2026

A triple agonist worth watching, with a number that is routinely quoted out of its timeframe.

Weight lossLong-acting GLP-1, GIP and glucagon triple agonistInvestigational
Dose0.5 to 8 mg weekly in phase 1; the phase 2 dose levels include amounts above 8 mg and are not individually published
FrequencyWeekly
RouteUnder the skin (subcutaneous)
StatusInvestigational
CycledNot cycled in the trials

See how this dose compares across the library →

01

What is HM15275?

Plain language first. The technical label stays, but it never stands alone.

Overview

An early weekly injection for weight loss that works on three targets instead of one.

The technical version

HM15275 is a long-acting GLP-1, GIP and glucagon triple receptor co-agonist in a 36-week phase 2 study for obesity, with phase 1 results reported only as a conference poster.

What it's used for

An investigational weekly injection for obesity that hits three metabolic receptors at once.

02

How does HM15275 work?

What it does in the body, and where.

HM15275 activates the GLP-1, GIP and glucagon receptors together, which is the same combination retatrutide uses. What differs between triple agonists is the balance between the three.

  1. 01
    Three receptors, deliberately unbalanced
    The developer describes it as rationally designed with balanced activity optimized for weight reduction and glycemic control. The ratio between the three activities is the design choice that separates one triple agonist from another, and it is not published in numbers.
  2. 02
    Glucagon is the part that burns rather than suppresses
    GLP-1 and GIP work largely through appetite and insulin. Adding glucagon receptor activity raises energy expenditure, which is the mechanism behind the hope that this class spares muscle while taking off fat.
  3. 03
    Long-acting through the developer's own platform
    The compound carries the company's half-life extension technology, which is what makes a weekly injection possible.
  4. 04
    Where it actually stands
    Phase 1 is done and reported only as a poster. Phase 2 finished enrolling 267 people against a 250 target and runs 36 weeks with percent change in body weight as the primary endpoint. Until that reports, the only human efficacy number is a four-week one.
Anatomical illustration highlighting metabolic organs
WHAT THIS COMPOUND ACTS ON:
GLP-1Fullness, slower stomachGIPInsulin after mealsglucagonBurns stored fuel
03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Obesity and overweight with a weight-related comorbidity, the phase 2 indicationtrial-protocol
  • Type 2 diabetes, a separate phase 2 program the developer has announcedInvestigational
  • Preserving lean mass, assessed in the phase 2 study and claimed preclinically, not demonstrated in peoplenone

The published record

Research index

0

Papers about HM15275 · this compound only

Searched: HM15275, LA-GLP/GIP/GCG, HM-OBCT-201.

3 papers tagged human · 0 not reviews or lab · 0 clinical trial publications

3 registered trials · none with posted results

Furthest stage reached: Phase 2, under way

Compare this against the whole library →

In animals0
In the lab0
Reviews0
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

HM15275 vial rendering
Compound field notes

At a glance

Four things to know about HM15275

01

Evidence

Investigational

02

Category

Weight loss and metabolic

03

Common vial

Varies

04

Half-life

Not published

04

How much, and do you cycle it?

The range, and whether you take breaks.

0.5 to 8 mg weekly in phase 1; the phase 2 dose levels include amounts above 8 mg and are not individually published, weekly. Not cycled in the trials Trial dose

Given weekly for the whole 36-week study period with the dose stepped up at the start, which is a ramp rather than a cycle.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not publishedNo figure

No measured half-life has been published. Weekly dosing in both the phase 1 and phase 2 studies implies a half-life engineered to support it, but implying is not measuring and no figure appears in anything read here.

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Enter the amount printed on your label.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: 0.5 up to 8 mgTrial dose

Choose your mix

mL water—units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW0 / 100 units
07

How do you store it?

Before mixing, and after.

Nothing to store: it is not sold anywhere.

HM15275 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.
  • Not applicable: this is an investigational compound with no approved use
  • Anyone outside a registered clinical trial, because there is no legitimate supply
  • People with type 2 diabetes, who are excluded from the phase 2 obesity study

Stop and get help

These are emergencies. Seek care.
  • Not applicable outside a clinical trial, where the protocol and the study doctor govern

Common effects

Expected, and usually mild.
  • Mostly mild gastrointestinal effects in phase 1, as described by the developer.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is HM15275 approved?

And where the numbers on this page come from.

No. HM15275 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

Guides for this compound

Sources

  • Hanmi Pharmaceutical, ObesityWeek 2025 poster P-218(2025)
    The developer's own phase 1 poster, which is the primary document for the dosing and the design. HM15275 is described as a novel long-acting GLP-1, GIP and glucagon triple co-agonist rationally designed with balanced activity optimized for weight reduction and glycemic control. The first-in-human study was NCT06481098, randomized, with cohorts of ten people each escalating through four dose steps: 0.5, 0.5, 2.0, 2.0 mg; 0.5, 1.0, 2.0, 4.0 mg; and 0.5, 2.0, 4.0, 8.0 mg. The poster's own conclusion is measured: weight loss observed over the short study duration suggests clinically meaningful effects and supports further investigation. It also states the phase 2 obesity study would start in the fourth quarter of 2025 as NCT07205900, with a phase 2 type 2 diabetes study planned for the first quarter of 2026.
  • Third-party trial listing for NCT07205900, Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus(2026)
    The phase 2 design, read from a third-party listing and not from the registry. ClinicalTrials.gov was tried at source for NCT07205900 and returned only its own site shell, with empty metadata and no study record, which is what that site does for a reader that cannot run its scripts. So the design below is reported at one remove and should be read that way. HM-OBCT-201 is described as a phase 2 randomized, double-blind, placebo-controlled, multicenter, parallel group study of HM15275 over 36 weeks in adults who are obese, with a body mass index of 30 to 50, or overweight, with a body mass index of 27 to under 30 and at least one weight-related comorbidity. Type 2 diabetes is an exclusion, as are obesity from an endocrine or genetic disorder and prior obesity surgery or device therapy within the stated windows.
  • BioSpectator, Hanmi completes US phase 2 enrollment for triple agonist HM15275(2026)
    Where enrollment landed and what the phase 1 number actually was. The developer said it completed US phase 2 enrollment with 267 patients against a 250 target, moving the registry status from recruiting to active and not recruiting, with completion expected in January 2027 and body weight change at 36 weeks as the primary endpoint alongside an assessment of lean mass. The same report gives the phase 1 figure in its own context: a maximum of 4.8 percent weight loss when 8 mg was given for four weeks, with the phase 2 study to include doses above 8 mg. It also records that phase 1 saw no serious adverse events or discontinuations, mostly mild gastrointestinal effects, and that the preclinical comparison claiming 10 percentage points more weight loss than competing triple agonists is the company's own.

Beyond these, 3 records are indexed for this compound. Browse the records